- Home
- PIII vs ENLV Comparison
PIII vs ENLV Comparison
Compare PIII & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- ENLV
- Stock Information
- Founded
- PIII 2015
- ENLV 2005
- Country
- PIII United States
- ENLV Israel
- Employees
- PIII N/A
- ENLV N/A
- Industry
- PIII Medical/Nursing Services
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- ENLV Health Care
- Exchange
- PIII Nasdaq
- ENLV Nasdaq
- Market Cap
- PIII 29.3M
- ENLV 26.6M
- IPO Year
- PIII N/A
- ENLV 1995
- Fundamental
- Price
- PIII $8.73
- ENLV $1.06
- Analyst Decision
- PIII Strong Buy
- ENLV Strong Buy
- Analyst Count
- PIII 3
- ENLV 2
- Target Price
- PIII $17.50
- ENLV $10.00
- AVG Volume (30 Days)
- PIII 3.7K
- ENLV 181.1K
- Earning Date
- PIII 11-14-2025
- ENLV 11-28-2025
- Dividend Yield
- PIII N/A
- ENLV N/A
- EPS Growth
- PIII N/A
- ENLV N/A
- EPS
- PIII N/A
- ENLV N/A
- Revenue
- PIII $1,461,823,000.00
- ENLV N/A
- Revenue This Year
- PIII N/A
- ENLV N/A
- Revenue Next Year
- PIII $10.45
- ENLV N/A
- P/E Ratio
- PIII N/A
- ENLV N/A
- Revenue Growth
- PIII 4.20
- ENLV N/A
- 52 Week Low
- PIII $5.80
- ENLV $0.81
- 52 Week High
- PIII $24.00
- ENLV $2.10
- Technical
- Relative Strength Index (RSI)
- PIII 48.37
- ENLV 47.24
- Support Level
- PIII $8.60
- ENLV $1.04
- Resistance Level
- PIII $8.88
- ENLV $1.10
- Average True Range (ATR)
- PIII 0.31
- ENLV 0.05
- MACD
- PIII -0.06
- ENLV -0.00
- Stochastic Oscillator
- PIII 13.72
- ENLV 22.22
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.